Q3 2025 Earnings Estimate for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Issued By Zacks Research

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Zacks Research cut their Q3 2025 earnings estimates for Vertex Pharmaceuticals in a report issued on Friday, April 19th. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will earn $3.74 per share for the quarter, down from their previous estimate of $3.75. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q1 2026 earnings at $3.77 EPS.

Several other equities research analysts also recently commented on the stock. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $440.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Guggenheim raised their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Truist Financial increased their price target on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $399.92 on Monday. The stock’s 50-day moving average is $413.23 and its 200-day moving average is $398.05. Vertex Pharmaceuticals has a 1-year low of $316.43 and a 1-year high of $448.40. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The stock has a market cap of $103.36 billion, a P/E ratio of 28.79, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the prior year, the firm earned $3.33 EPS.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Capital World Investors boosted its holdings in shares of Vertex Pharmaceuticals by 21.3% in the fourth quarter. Capital World Investors now owns 21,805,770 shares of the pharmaceutical company’s stock worth $8,872,586,000 after acquiring an additional 3,824,103 shares during the period. Norges Bank bought a new position in Vertex Pharmaceuticals in the 4th quarter worth about $1,237,877,000. Public Employees Retirement Association of Colorado boosted its stake in Vertex Pharmaceuticals by 2,272.6% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 434,874 shares of the pharmaceutical company’s stock worth $176,946,000 after purchasing an additional 416,545 shares during the period. abrdn plc increased its position in shares of Vertex Pharmaceuticals by 196.0% during the fourth quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock valued at $236,410,000 after buying an additional 384,730 shares during the period. Finally, Global Assets Advisory LLC bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at about $137,975,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock worth $5,203,249 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.